Traditional corticosteroids for induction of remission in Crohn's disease

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2008, Pages

  Benchimol, Eric I ^a   Seow, C H ^b   Steinhart, A H ^b   Griffiths, A M ^b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; MESALAZINE; METHYLPREDNISOLONE; PLACEBO; PREDNISONE; SALAZOSULFAPYRIDINE;

CLINICAL TRIAL; COCHRANE LIBRARY; COMPUTER PROGRAM; CONFIDENCE INTERVAL; CORTICOSTEROID THERAPY; CROHN DISEASE; CUSHINGOID SYNDROME; DATA EXTRACTION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EMBASE; FOLLOW UP; HEADACHE; HERPES ZOSTER; HUMAN; LOW DRUG DOSE; MEDLINE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; REMISSION; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS HEPATITIS; VOMITING;

EID: 44949173162     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006792.pub2     Document Type: Review

References (58)

1. Gross 1995 {published data only} Gross V, Andus T, Fischbach W, Weber A, Gierend M, Hartmann F, et al.Comparison between high dose 5-aminosalicylic acid and 6-methylprednisolone in active Crohn's ileocolitis. A multicenter randomized double-blind study. German 5-ASA Study Group. Z Gastroenterol 1995;33(10):581-4.
2. Malchow 1984 {published data only} Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, et al.European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984;86(2):249-66. [MEDLINE: CHECK].
3. Martin 1990 {published data only} Martin F, Sutherland L, Beck IT, Anderson AH, Williams CN, Saibil F, et al.Oral 5-ASA versus prednisone in short term treatment of Crohn's disease: A multicentre controlled trial. Can J Gastroenterol 1990;4(7):452-7.
4. Prantera 1999 {published data only} Prantera C, Cottone M, Pallone F, Annese V, Franze A, Cerutti R, et al.Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial. Gastroenterology 1999;116(3):521-6. [MEDLINE: CHECK].
5. Scholmerich 1990 {published data only} Scholmerich J, Jenss H, Hartmann F, Dopfer H. Oral 5-aminosalicylic acid versus 6-methylprednisolone in active Crohn's disease. Can J Gastroenterol 1990;4(7):446-51.
6. Singleton 1979a {published data only} Singleton JW, Law DH, Kelley ML, Jr, Mekhjian HS, Sturdevant RA. National Cooperative Crohn's Disease Study: adverse reactions to study drugs. Gastroenterology 1979;77(4 Pt 2):870-82. [MEDLINE: CHECK].
7. Summers 1979 {published data only} Summers RW, Switz DM, Sessions JT Jr, Becktel JM, Best WR, Kern F Jr, et al.National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979;77(4 Pt 2):847-69. [MEDLINE: CHECK].
8. Winship 1979 {published data only} Winship DH, Summers RW, Singleton JW, Best WR, Becktel JM, Lenk LF, et al.National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology 1979;77(4 Pt 2): 829-42. [MEDLINE: CHECK].
9. Bergman 1976 Bergman L, Krause U. Postoperative treatment with corticosteroids and salazosulphapyridine (Salazopyrin) after radical resection for Crohn's disease. Scand J Gastroenterol 1976;11(7):651-6.
10. Brignola 1994 Brignola C, De Simone G, Belloli C, Iannone P, Belluzzi A, Gionchetti P, et al.Steroid treatment in active Crohn's disease: a comparison between two regimens of different duration. Aliment Pharmacol Ther 1994;8(4):465-8.
11. Chun 1998 Chun A, Chadi RM, Korelitz BI, Colonna T, Felder JB, Jackson MH, et al.Intravenous corticotrophin vs. hydrocortisone in the treatment of hospitalized patients with Crohn's disease: a randomized double-blind study and follow-up. Inflamm Bowel Dis 1998;4(3):177-81.
12. Gaia 1979 Gaia E, Morello C, Roatta L, Cavallero M, Bonard R, Banche M. [Use of a chronomulticorticoid in the treatment of Crohn's disease]. Clin Ter 1979;90(4):325-33.
13. Jenss 1989 Jenss H, Hartmann F, Scholmerich J. 5-aminosalicylic acide versus methylprednisolone in the treatment of active Crohn disease. Gastroenterology 1989;96(5 Part 2):A239.
14. Jenss 1990 Jenss H, Hartmann F, Scholmerich J. Coated mesalazine vs. methylprednisolone in the treatment of active Crohn's disease: A randomized double-blind study (abstract). Gastroenterology 1990;98(5 Part 2):A178.
15. Landi 1992 Landi B, Anh TN, Cortot A, Soule JC, Rene E, Gendre JP, et al.Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1992;102(5):1647-53.
16. Maier 1990 Maier K, Frick HJ, Von Gaisberg U, Teufel T, Klotz U. Clinical efficacy of oral mesalazine in Crohn's disease. Can J Gastroenterol 1990;4(1):13-8.
17. Modigliani 1990 Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP, et al.Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990;98(4):811-8.
18. Modigliani 1996 Modigliani R, Colombel JF, Dupas JL, Dapoigny M, Costil V, Veyrac M, et al.Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1996;110(3):688-93.
19. Rijk 1991 Rijk MC, van Hogezand RA, van Lier HJ, van Tongeren JH. Sulphasalazine and prednisone compared with sulphasalazine for treating active Crohn disease. A double-blind, randomized, multicenter trial. Ann Intern Med 1991;114(6):445-50.
20. Schneider 1985 Schneider MU, Laudage G, Guggenmoos-Holzmann I, Riemann JF. [Metronidazole in the treatment of Crohn disease. Results of a controlled randomized prospective study]. Dtsch Med Wochenschr 1985;110(45):1724-30.
21. Singleton 1979b Singleton JW, Summers RW, Kern F Jr, Becktel JM, Best WR, Hansen RN, et al.A trial of sulfasalazine as adjunctive therapy in Crohn's disease. Gastroenterology 1979;77(4 Pt 2):887-97.
22. Akobeng 2004 Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2004, Issue 1.Art. No.: CD003574. DOI: 10.1002/14651858.CD003574.pub2.
23. Akobeng 2005 Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's Disease. Cochrane Database of Systematic Reviews 2005, Issue 1.Art. No.: CD003715. DOI:10.1002/14651858.CD003715.pub2.
24. Alfadhli 2005 Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database of Systematic Reviews 2005, Issue 1.Art. No.: CD003459. DOI: 10.1002/14651858.CD003459.pub2.
25. Azad Khan 1977 Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977;2(8044):892-5.
26. Barnes 1993 Barnes PJ, Adcock I. Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sci 1993;14(12): 436-41.
27. Baumgart 2007 Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007;369(9573):1641-57.
28. Bebb 2004 Bebb JR, Scott BB. How effective are the usual treatments for Crohn's disease?. Aliment Pharmacol Ther 2004;20(2):151-9.
29. Best 1976 Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70(3):439-44.
30. Bousvaros 2007 Bousvaros A, Antonioli DA, Colletti RB, Dubinsky MC, Glickman JN, Gold BD, et al.Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. J Pediatr Gastroenterol Nutr 2007;44(5):653-74.
31. Clark 1999 Clark HD, Wells GA, Huet C, McAlister FA, Salmi LR, Fergusson D, et al.Assessing the quality of randomized trials: reliability of the Jadad scale. Control Clin Trials 1999;20(5):448-52.
32. Desreumaux 2006 Desreumaux P, Ghosh S. Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. Aliment Pharmacol Ther 2006;24 Suppl 1:2-9.
33. Feagan 1998 Feagan BG. Aminosalicylates for active disease and in the maintenance of remission in Crohn's disease. Eur J Surg 1998;164(12):903-9. [MEDLINE: CHECK].
34. Hanauer 2004 Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2004;2(5):379-88.
35. Hanauer 2005 Hanauer SB. The case for using 5-aminosalicyclates in Crohn's disease: pro. Inflamm Bowel Dis 2005;11(6):609-12.
36. Hardy 1993 Hardy JG, Harvey WJ, Sparrow RA, Marshall GB, Steed KP, Macarios M, et al.Localization of drug release sites from an oral sustained-release formulation of 5-ASA (Pentasa) in the gastrointestinal tract using gamma scintigraphy. J Clin Pharmacol 1993;33(8):712-8.
37. Harvey 1980 Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980;1(8167):514.
38. Higgins 2003 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557- 60.
39. Higgins 2005 Higgins JPT, Green S, editors. Assessment of study quality. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]; Section 6. The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & Sons, 2006.
40. Hyams 1991 Hyams JS, Ferry GD, Mandel FS, Gryboski JD, Kibort PM, Kirschner BS, et al.Development and validation of a pediatricCrohn's disease activity index. J Pediatr Gastroenterol Nutr 1991;12(4):439-47.
41. Hyams 2000 Hyams JS. Corticosteroids in the treatment of gastrointestinal disease. Curr Opin Pediatr 2000;12(5):451-5.
42. Hyams 2005 Hyams JS. Inflammatory bowel disease. Pediatr Rev 2005;26(9):314-20.
43. Jadad 1996 Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al.Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996;17(1):1- 12.
44. Juni 2001 Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42-6.
45. Kamm 2005 Kamm MA. Debate: should mesalamine be used in Crohn's disease?: comments and conclusions. Inflamm Bowel Dis 2005;11(6):616-7.
46. Kamm 2006 Kamm MA. Review article: biological drugs in Crohn's disease. Aliment Pharmacol Ther 2006;24 Suppl 3:80-9.
47. Lichtenstein 2006 Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130(3):940-87.
48. MacDonald 2007 MacDonald JK, McDonald JW. Natalizumab for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2007, Issue 1.Art. No.: CD006097. DOI: 10.1002/14651858.CD006097. pub2.
49. Otley 2005 Otley A, Steinhart AH. Budesonide for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2005, Issue 4.Art. No.: CD000296. DOI:10.1002/14651858.CD000296.pub2.
50. Salomon 1992 Salomon P, Kornbluth A, Aisenberg J, Janowitz HD. How effective are current drugs for Crohn's disease? A meta-analysis. J Clin Gastroenterol 1992;14(3):211-5.
51. Sandborn 2000 Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database of Systematic Reviews 2000, Issue 2.
52. Sandborn 2003 Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 2003;17(1):29-42.
53. Silverberg 2005 Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19 Suppl A:5-36.
54. Stange 2005 Stange EF. The case against using 5-aminosalicyclates in Crohn's disease: con. Inflamm Bowel Dis 2005;11(6):613-5.
55. Truelove 1954 Truelove SC, Witts LJ. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. Br Med J 1954;2(4884):375-8.
56. Van Hees 1980 van Hees PA, van Elteren PH, van Lier HJ, van Tongeren JH. An index of inflammatory activity in patients with Crohn's disease. Gut 1980;21(4):279-86.
57. Yang 2002 Yang YX, Lichtenstein GR. Corticosteroids in Crohn's disease. Am J Gastroenterol 2002;97(4):803-23.
58. Zachos 2007 Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2007, Issue 1.Art. No.: CD000542. DOI: 10.1002/14651858.CD000542.pub2.